New Things | Domestic New Crown Special Pills finalized circulating suppliers

On July 19, Teng Shengbo Pharmaceutical announced that his subsidiary Teng Shenghua Chuangji reached strategic cooperation with China Resources Pharmaceutical Business. Drug storage, channel distribution, hospital access and other links.

This is the first time that the new crown of Tengshengbo Medicine has determined the circulation service provider. Earlier, Phard's new crown oral medication Paxlovid entered China, and found that China Medicine was responsible for agency, and the circulation business was responsible for different domestic regions by circulating giants such as Chinese medicine.

In July of this year, Tengshengbo Medicine has cooperated with China Resources Pharmaceutical Business to send the first batch of new commercialized crowns and antibody drugs to Shenzhen Third People's Hospital, and completed the first patient in the country. According to Nandu reports at the time, the medicine was stored in the cold chain environment of 2-8 ° C.

The price of this neutralized antibody combination therapy is not low. According to the Gansu Provincial Public Resources Trading Center, the drug is in the hanging network of Gansu Province. Two antibodies of 0.5G specifications each, each determined national lowest price is 2417 yuan.

According to the propaganda draft of Teng Shengbo Pharmaceutical, China Resources Pharmaceutical Business, as one of the well -known domestic pharmaceutical circulation enterprises, has a marketing point in 31 provinces and cities, and the supply chain is relatively complete. Judging from this statement, China Resources Pharmaceutical Business is likely to be this exclusive agent dealer of neutralized antibody therapy.

Once the cooperation announcement was issued, the stock price of Teng Shengbo Yao ushered in a significant rise, and eventually closed at 6.67%.

### ## 和#

- END -